argenx SE (ARGX.BR)
EUR 610.0
(1.77%)
EUR 610.0
(1.77%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -417.15 Million EUR | 42.03% |
| 2022 | -719.66 Million USD | -106.36% |
| 2021 | -348.74 Million USD | 32.13% |
| 2020 | -513.83 Million EUR | -156.9% |
| 2019 | -200.01 Million EUR | -113.62% |
| 2018 | -93.62 Million EUR | -240.32% |
| 2017 | -27.51 Million EUR | -22.15% |
| 2016 | -22.52 Million EUR | -32.02% |
| 2015 | -17.06 Million EUR | -30.6% |
| 2014 | -13.06 Million EUR | -51.85% |
| 2013 | -8.6 Million EUR | 35.28% |
| 2012 | -13.29 Million EUR | -181.75% |
| 2011 | -4.71 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -45.46 Million EUR | -69.8% |
| 2024 Q1 | -93.42 Million USD | 36.9% |
| 2023 Q3 | -80.58 Million USD | 21.06% |
| 2023 Q1 | -103.74 Million USD | 8.8% |
| 2023 Q2 | -102.09 Million USD | 1.59% |
| 2023 FY | -417.15 Million EUR | 42.03% |
| 2023 Q4 | -138.62 Million USD | -72.02% |
| 2022 FY | -719.66 Million USD | -106.36% |
| 2022 Q3 | -208.63 Million USD | -19.53% |
| 2022 Q4 | -113.75 Million USD | 45.48% |
| 2022 Q1 | -222.72 Million USD | 3.55% |
| 2022 Q2 | -174.54 Million USD | 21.63% |
| 2021 Q1 | -13 Thousand EUR | 99.99% |
| 2021 FY | -348.74 Million USD | 32.13% |
| 2021 Q2 | 95.13 Million USD | 731915.38% |
| 2021 Q3 | -212.95 Million USD | -323.84% |
| 2021 Q4 | -230.91 Million USD | -8.43% |
| 2020 Q4 | -227.44 Million EUR | 0.0% |
| 2020 FY | -513.83 Million EUR | -156.9% |
| 2020 Q2 | -210.97 Million EUR | 0.0% |
| 2019 Q1 | -6.78 Million EUR | 82.47% |
| 2019 FY | -200.01 Million EUR | -113.62% |
| 2019 Q4 | -75.19 Million EUR | -53.81% |
| 2019 Q3 | -48.88 Million EUR | 11.34% |
| 2019 Q2 | -55.14 Million EUR | -712.86% |
| 2018 Q2 | -11.91 Million EUR | 31.7% |
| 2018 Q3 | -25.58 Million EUR | -114.78% |
| 2018 FY | -93.62 Million EUR | -240.32% |
| 2018 Q1 | -17.44 Million EUR | -49.3% |
| 2018 Q4 | -38.69 Million EUR | -51.23% |
| 2017 Q1 | -8.97 Million EUR | -6.57% |
| 2017 Q2 | 1.24 Million EUR | 113.9% |
| 2017 Q4 | -11.68 Million EUR | -44.13% |
| 2017 Q3 | -8.1 Million EUR | -749.93% |
| 2017 FY | -27.51 Million EUR | -22.15% |
| 2016 Q3 | -5.92 Million EUR | -23.23% |
| 2016 Q1 | -3.37 Million EUR | 39.09% |
| 2016 FY | -22.52 Million EUR | -32.02% |
| 2016 Q2 | -4.8 Million EUR | -42.66% |
| 2016 Q4 | -8.41 Million EUR | -42.08% |
| 2015 Q2 | -4.63 Million EUR | -32.48% |
| 2015 FY | -17.06 Million EUR | -30.6% |
| 2015 Q4 | -5.53 Million EUR | -62.93% |
| 2015 Q3 | -3.39 Million EUR | 26.71% |
| 2015 Q1 | -3.49 Million EUR | 25.08% |
| 2014 Q2 | -3.73 Million EUR | -43.16% |
| 2014 Q3 | -2.05 Million EUR | 45.08% |
| 2014 Q4 | -4.66 Million EUR | -127.61% |
| 2014 FY | -13.06 Million EUR | -51.85% |
| 2014 Q1 | -2.6 Million EUR | -23.68% |
| 2013 Q2 | -4 Million EUR | -67.07% |
| 2013 Q3 | -97.6 Thousand EUR | 97.56% |
| 2013 Q4 | -2.1 Million EUR | -2061.35% |
| 2013 Q1 | -2.39 Million EUR | 0.0% |
| 2013 FY | -8.6 Million EUR | 35.28% |
| 2012 FY | -13.29 Million EUR | -181.75% |
| 2011 FY | -4.71 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -12126.066% |
| ABIVAX Société Anonyme | -127.37 Million EUR | -227.498% |
| Adocia SA | -17.62 Million EUR | -2267.231% |
| Aelis Farma SA | -6.46 Million EUR | -6356.483% |
| Biophytis S.A. | -14.33 Million EUR | -2810.44% |
| Advicenne S.A. | -6.45 Million EUR | -6360.483% |
| genOway Société anonyme | 2.06 Million EUR | 20298.236% |
| IntegraGen SA | -183.77 Thousand EUR | -226897.53% |
| Medesis Pharma S.A. | -4.22 Million EUR | -9763.318% |
| Neovacs S.A. | -6.9 Million EUR | -5939.094% |
| NFL Biosciences SA | -4.43 Million EUR | -9315.662% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -53502.355% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -13196.767% |
| Sensorion SA | -22.31 Million EUR | -1769.752% |
| Theranexus Société Anonyme | -7.64 Million EUR | -5357.496% |
| TME Pharma N.V. | -5.62 Million EUR | -7317.378% |
| Valbiotis SA | -7.16 Million EUR | -5726.164% |
| TheraVet SA | -2.17 Million EUR | -19078.504% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -1956.158% |
| BioSenic S.A. | -7.04 Million EUR | -5825.474% |
| Celyad Oncology SA | -8.45 Million EUR | -4832.64% |
| DBV Technologies S.A. | -85.24 Million EUR | -389.351% |
| Galapagos NV | -88.26 Million EUR | -372.625% |
| Genfit S.A. | -26.58 Million EUR | -1469.426% |
| GeNeuro SA | -14.35 Million EUR | -2805.514% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -2508.35% |
| Innate Pharma S.A. | -12.66 Million EUR | -3192.709% |
| Inventiva S.A. | -102.7 Million EUR | -306.151% |
| MaaT Pharma SA | -19.94 Million EUR | -1991.728% |
| MedinCell S.A. | -20.97 Million EUR | -1888.623% |
| Nanobiotix S.A. | -26.77 Million EUR | -1457.763% |
| Onward Medical N.V. | -35.46 Million EUR | -1076.306% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -9069.832% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -1714.815% |
| Oxurion NV | -12.11 Million EUR | -3344.702% |
| Pharming Group N.V. | -4.87 Million EUR | -8449.023% |
| Poxel S.A. | -28.76 Million EUR | -1350.262% |
| GenSight Biologics S.A. | -29.69 Million EUR | -1304.746% |
| Transgene SA | -30.01 Million EUR | -1289.955% |
| Financière de Tubize SA | -2.14 Million EUR | -19357.016% |
| UCB SA | 604 Million EUR | 169.065% |
| Valneva SE | -82.08 Million EUR | -408.184% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | -1346.591% |